Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664214 | 0.96 | DPP3 (0.57) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL29466818 | 0.96 | SLC6A2 (0.64) | DPP3SLC6A2OPRM1ACEOPRD1 | |
| SCHEMBL30240001 | 0.93 | SLC6A2 (0.57) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL31016729 | 0.93 | SLC6A2 (0.59) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL31184433 | 0.92 | SLC6A2 (0.63) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL11091524 | 0.92 | SLC6A2 (0.63) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL29641478 | 0.91 | SLC6A2 (0.57) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL29602423 | 0.90 | SLC6A2 (0.62) | DPP3SLC6A2CMA1OPRM1ACE | |
| SCHEMBL11782844 | 0.89 | LNPEP (0.64) | DPP3SLC6A2CMA1 | |
| SCHEMBL11782852 | 0.89 | LNPEP (0.64) | DPP3SLC6A2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241640-B | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119241640-A | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-119241640-B | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119241640-B | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119286742-B | Lactobacillus delbrueckii subspecies lactis YN-01, products prepared from same and application thereof | 内蒙古农业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119286742-A | Lactobacillus delbrueckii subspecies lactis YN-01, products prepared from same and application thereof | 内蒙古农业大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-119241640-A | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119241640-A | Tripeptide for promoting bone growth | 杭州康源食品科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-111164092-B | Process for producing peptide compound | 日产化学株式会社 | 2023-12-26 | — | — | CN | disclosed |
| CN-117024519-A | Soybean enzymolysis polypeptide and application thereof as elastase inhibitor | 广东海通药业有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP3 25/4885SLC6A2 2481/4885CMA1 3567/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | DPP3 64/4885SLC6A2 3426/4885CMA1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.